The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Abstract
Both alcoholic liver disease (ALD) and nonalcoholic fatty liver disease are characterized by massive lipid accumulation in the liver accompanied by inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma in a substantial subgroup of patients. At several stages in these diseases, mediators of the immune system, such as cytokines or inflammasomes, are crucially involved. In ALD, chronic ethanol exposure sensitizes Kupffer cells to activation by lipopolysaccharides through Toll‐like receptors, e.g., Toll‐like receptor 4. This sensitization enhances the production of various proinflammatory cytokines such as interleukin‐1 (IL‐1) and tumor necrosis factor‐alpha, thereby contributing to hepatocyte dysfunction, necrosis, and apoptosis and the generation of extracellular matrix proteins leading to fibrosis/cirrhosis. Indeed, neutralization of IL‐1 by IL‐1 receptor antagonist has recently been shown to potently prevent liver injury in murine models of ALD. As IL‐1 is clearly linked to key clinical symptoms of acute alcoholic hepatitis such as fever, neutrophilia, and wasting, interfering with the IL‐1 pathway might be an attractive treatment strategy in the future. An important role for IL‐1‐type cytokines and certain inflammasomes has also been demonstrated in murine models of nonalcoholic fatty liver disease. IL‐1‐type cytokines can regulate hepatic steatosis; the NLR family pyrin domain containing 3 inflammasome is critically involved in metabolic dysregulation. Conclusion: IL‐1 cytokine family members and various inflammasomes mediate different aspects of both ALD and nonalcoholic fatty liver disease. (H epatology 2016;64:955‐965)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Self-citationInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
What we talk about when we talk about fat
Rosen, E. D., & Spiegelman, B. M. (2014) · Cell · doi:10.1016/j.cell.2013.12.012 · Cited by 2,373
The interleukin-1 family: back to the future
Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945 · cited 3×
“These mediators are mainly proinflammatory but can also be anti-inflammatory and are important in almost all inflammatory conditions, exerting their specific effects through IL-1Rs 1-10.((6)) They are also involved in the differentiation and function of many innate and lymphoid cells, direct many complex inflammatory…”
BackgroundInfluentialTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,682
Cited by
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Adams, L. A., Anstee, Q. M., Tilg, H., & Targher, G. (2017) · Gut · doi:10.1136/gutjnl-2017-313884 · Cited by 1,174
Self-citationRecovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease
Grander, C., Adolph, T. E., Wieser, V., Lowe, P., Wrzosek, L., Gyongyosi, B., Ward, D. V., Grabherr, F., Gerner, R. R., Pfister, A., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313432 · Cited by 618
Self-citationLiver sinusoidal endothelial cells — gatekeepers of hepatic immunity
Shetty, S., Lalor, P. F., & Adams, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0020-y · Cited by 523
Li, L., Liu, D. ‐., Yan, H. ‐., Wang, Z. ‐., Zhao, S. ‐., & Wang, B. (2016) · Obesity Reviews · doi:10.1111/obr.12407 · Cited by 439
Inflammatory pathways in alcoholic steatohepatitis
Gao, B., Ahmad, M. F., Nagy, L. E., & Tsukamoto, H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.023 · Cited by 392
Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure
Woolbright, B. L., & Jaeschke, H. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.017 · Cited by 390
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Anstee, Q. M., Mantovani, A., Tilg, H., & Targher, G. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0010-0 · Cited by 310
Self-citationRecent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease
Wu, X., Fan, X., Miyata, T., Kim, A., Cajigas-Du Ross, C. K., Ray, S., Huang, E., Taiwo, M., Arya, R., Wu, J., et al. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-030435 · Cited by 289
Vallianou, N., Christodoulatos, G. S., Karampela, I., Tsilingiris, D., Magkos, F., Stratigou, T., Kounatidis, D., & Dalamaga, M. (2021) · Biomolecules · doi:10.3390/biom12010056 · Cited by 289
Cytokines and abnormal glucose and lipid metabolism
Shi, J., Fan, J., Su, Q., & Yang, Z. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00703 · Cited by 282
Lytic cell death in metabolic liver disease
Gautheron, J., Gores, G. J., & Rodrigues, C. M. P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.001 · Cited by 225
Athyros, V. G., Alexandrides, T. K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E. S., Goudevenos, J., Elisaf, M. S., Germanidis, G., Giouleme, O., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.014 · Cited by 219
The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
Cai, J., Zhang, X., & Li, H. (2019) · Hepatology · doi:10.1002/hep.30506 · Cited by 207
Innate Immune Cell Trafficking and Function During Sterile Inflammation of the Liver
McDonald, B., & Kubes, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.048 · Cited by 123
Role of Oxidative Stress in Liver Disorders
Conde de la Rosa, L., Goicoechea, L., Torres, S., Garcia-Ruiz, C., & Fernandez-Checa, J. C. (2022) · Livers · doi:10.3390/livers2040023 · Cited by 107
Publisher Correction: The gut–liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0031-8 · Cited by 70
Meyer, M., Schwärzler, J., Jukic, A., & Tilg, H. (2024) · Biomolecules · doi:10.3390/biom14040476 · Cited by 50
Self-citationInflammation in Alcohol-Associated Hepatitis: Pathogenesis and Therapeutic Targets
Feng, D., Hwang, S., Guillot, A., Wang, Y., Guan, Y., Chen, C., Maccioni, L., & Gao, B. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.04.009 · Cited by 44
Murtha-Lemekhova, A., Fuchs, J., Ghamarnejad, O., Nikdad, M., Probst, P., & Hoffmann, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-92888-4 · Cited by 36
A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?
Tilg, H., Effenberger, M., & Adolph, T. E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1681397 · Cited by 28
Self-citationDesign of a multicenter randomized clinical trial for treatment of alcohol-associated hepatitis
Tu, W., Gawrieh, S., Dasarathy, S., Mitchell, M. C., Simonetto, D. A., Patidar, K. R., McClain, C. J., Bataller, R., Szabo, G., Tang, Q., et al. (2023) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2023.101074 · Cited by 21
Roles of Trained Immunity in the Pathogenesis of Cholangiopathies: A Therapeutic Target
Yan, C., Koda, S., Wu, J., Zhang, B., Yu, Q., Netea, M. G., Tang, R., & Zheng, K. (2020) · Hepatology · doi:10.1002/hep.31395 · Cited by 21
“The best known are NLRP3 (NOD, LRR, and pyrin domain containing 3) and its related molecules of the inflammasome.(31) Activation of NLRP3 leads to cleavage of procaspase-1 into activated caspase-1 and the maturation and secretion of IL-1β and IL-18, inducing”
Background
Metadata
- Authors
- Tilg, H., Moschen, A. R., & Szabo, G.
- Venue
- Hepatology
- Published
- 2016-03-09
- Volume
- 64
- Issue
- 3
- Pages
- 955-965
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2514873437
- Cited by
- 319
- References
- 94
- FWCI
- 26.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.